• Cinnie Soekojo, Lenith Tai Jit Cheng, Wee Ming Peh, Sanjay de Mel, Melissa Ooi, Ying-Hwey Nai, Anthonin Reilhac, Lih Kin Khor, and Wee Joo Chng.
• Department of Haematology-Oncology, National University Cancer Institute, Singapore.
• Ann Acad Med Singap. 2023 Nov 29; 52 (11): 590600590-600.

IntroductionThis study aimed to evaluate the clinical utility of positron emission tomography/magnetic resonance imaging (PET/MRI), especially in comparison with PET/computed tomography (CT), which has been widely used in clinical practice in multiple myeloma.MethodF-18 fluorodeoxyglucose PET/MRI and PET/ CT studies were done at baseline and when at least a partial response to treatment was achieved. These were done for newly-diagnosed myeloma patients who have not had more than 1 cycle of anti-myeloma treatment, or for relapsed and/or refractory myeloma patients before the start of next line of therapy.ResultsPET/MRI correlated significantly with PET/CT, in terms of number of lesions detected, standardised uptake value (SUVmean and SUVmax, both at baseline and post-treatment. PET/MRI and PET/CT correlated with survival at baseline, but not post-treatment.ConclusionIn this study, PET/MRI was more sensitive in detecting early disease and disease resolution post-treatment, compared with PET/CT. However, PET/MRI was less sensitive in detecting lesions in the ribs, clavicle and skull.

26 keywords...

hide…